Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 19, 2014

View Archived Issues

Whole-exome sequencing links motor neuron disease and neurodegenerative disorders

Zenith Epigenetics identifies new compounds for epigenetics drug discovery

Catalyst Biosciences presents new polypeptides for coagulation disorders

FDA grants orphan drug status to "lost" drug for AML

Prana Biotechnology reports phase II results in Huntington's disease trial

Researchers at Biogen Idec prepare novel autotaxin inhibitors

Elite Pharmaceuticals reports data from pilot bioequivalence study of ELI-201

Supplemental NDA for Lymphoseek granted priority review by FDA

New seriniquinone derivatives with utility for cancer

Servier Canada invests in two research projects supported by Quebec government

French group discloses novel CYP26A1 inhibitors for dermatological disorders

RaQualia Pharma collaborates with Nagoya University

Millennium Pharmaceuticals synthesizes new UBA6 inhibitors for cancer

CNB-001 demonstrates promising neuroprotective activity in vivo

Genfit's GFT-505 granted FDA fast track designation

Boehringer Ingelheim divulges novel PDE2A inhibitors

Dynavax withdraws European marketing application for Heplisav

Japanese researchers design new delta opioid receptor agonists

Vital Therapies enrolls first subject in Europe in VTI-208 study

DNA hypermethylation associated with shortened PFS in patients with RCC

Second phase Ib trial of OMP-54F28 with Nexavar in HCC begins

International Stem Cell Corp. and FDA hold pre-IND meeting for Parkinson's disease cell therapy

FDA grants accelerated approval to Northera in symptomatic NOH

Eleven Biotherapeutics begins pivotal phase III study of EBI-005

FDA approves California Stem Cell's phase II stem trial for ovarian cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...